Eli Lilly says weight-loss drug cut diabetes risk by 94% in trial

(Reuters) – Eli Lilly said on Tuesday its weight loss drug cut the risk of developing diabetes by 94% in patients with pre-diabetes or those who were obese or overweight in a long-term study.

Treatment with tirzepatide, which is the active ingredient in Lilly’s Zepbound and Mounjaro treatments, also resulted in 22.9% average decrease in body weight compared to 2.1% for placebo, the company said.

(Reporting by Manas Mishra in Bengaluru; Editing by Shinjini Ganguli)